p16(CDKN2) gene polymorphism:: association with histologic subtypes of epithelial ovarian cancer in China

被引:18
|
作者
Yan, L. [1 ,2 ]
Na, W. [2 ]
Shan, K. [3 ]
Xiao-Wei, M. [3 ]
Wei, G. [2 ]
Shu-Cheng, C. [3 ]
机构
[1] Hebei Med Univ, Hosp 4, Hebei Canc Inst, Shijiazhuang 050011, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Mol Biol, Shijiazhuang 050011, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Obstet & Gynaecol, Shijiazhuang 050011, Peoples R China
基金
美国国家科学基金会;
关键词
epithelial ovarian cancer; haplotype; p16; single nucleotide polymorphism; susceptibility;
D O I
10.1111/j.1525-1438.2007.00953.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
p16 is an important tumor suppressor gene, which is inactivated in many kinds of tumors. The common variants of p16 may be associated with the risk of certain tumors development. We analyzed the frequency of two adjacent polymorphisms in p16 exon 3 (540C -> G and 580C -> T) and their haplotype in blood samples from epithelial ovarian cancer (EOC) patients and healthy controls using polymerase chain reaction-restriction fragment length polymorphism. The results showed that the genotype frequency of p16 580C -> T polymorphism was significantly different among histologic subtypes of EOC (P = 0.02). T allele carriers significantly reduced the risk of serous EOC; the adjusted odds ratio was 0.40 (95% CI = 0.19-0.84). There are neither association between p16 540C -> G polymorphism and EOC development, progression, nor association between the haplotypes of two single nucleotide polymorphisms and the tumor development. Our results suggested that the p16 580C -> T polymorphism might affect the individual susceptibility to specific subtypes of EOC. Different types of ovarian cancer might adopt distinct carcinogenetic pathways. However, this result may be further validated in a larger sample of patients.
引用
收藏
页码:30 / 35
页数:6
相关论文
共 50 条
  • [1] A frequent polymorphism in exon 1 of the p16/CDKN2 gene
    Fueyo, J
    GomezManzano, C
    Yung, WKA
    Zhang, W
    Lee, PSY
    Majumder, S
    Pershouse, M
    Levin, VA
    Kyritsis, AP
    [J]. MOLECULAR AND CELLULAR PROBES, 1995, 9 (06) : 465 - 466
  • [2] Analysis on point mutation of the cdkn2/p16 gene in lung cancer
    Su, Changqing
    Ye, Yukun
    Wang, Dong
    Cao, Xiangrong
    Li, Shufeng
    Shan, Xiangnian
    [J]. Chinese Journal of Medical Genetics, 2002, 19 (01) : 37 - 40
  • [3] Inactivation of the p16/CDKN2 gene in carcinomas of the hypopharynx
    Liengswangwong, U
    Konishi, N
    Hiasa, Y
    Naito, H
    Yane, K
    [J]. CANCER LETTERS, 1999, 143 : S33 - S33
  • [4] Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas
    Ono, Y
    Ueki, K
    Joseph, JT
    Louis, DN
    [J]. ACTA NEUROPATHOLOGICA, 1996, 91 (03) : 221 - 225
  • [5] CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas
    Piva, R
    Cavalla, P
    Bortolotto, S
    Cordera, S
    Grosso, R
    Richiardi, P
    Dutto, A
    Schiffer, D
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 1998, 12 (01) : 55 - 58
  • [6] Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds
    Holland, EA
    Beaton, SC
    Becker, TM
    Grulet, OMC
    Peters, BA
    Rizos, H
    Kefford, RF
    Mann, GJ
    [J]. ONCOGENE, 1995, 11 (11) : 2289 - 2294
  • [7] Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas
    Esteve, A
    MartelPlanche, G
    Sylla, BS
    Hollstein, M
    Hainaut, P
    Montesano, R
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1996, 66 (03) : 301 - 304
  • [8] Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme
    Hayashi, Y
    Ueki, K
    Waha, A
    Wiestler, OD
    Louis, DN
    vonDeimling, A
    [J]. BRAIN PATHOLOGY, 1997, 7 (03) : 871 - 875
  • [9] Adenoviral p16/CDKN2 gene transfer to malignant glioma: Role of p16 in growth, invasion, and senescence
    Kim, SK
    Wang, KC
    Cho, BK
    Lim, SY
    Kim, YY
    Oh, CW
    Chung, YN
    Kim, CY
    Lee, CT
    Kim, HJ
    [J]. ONCOLOGY REPORTS, 2003, 10 (05) : 1121 - 1126
  • [10] Mutations, methylation and expression of CDKN2α/p16 gene in colorectal cancer and normal colonic mucosa
    Trzeciak, L
    Hennig, E
    Kolodziejski, J
    Nowacki, M
    Ostrowski, J
    [J]. CANCER LETTERS, 2001, 163 (01) : 17 - 23